Drug
Brivanib
Brivanib: highest development phase Phase 2, developed by Zai Lab. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brivanib 800 mg, QD NCT03516071 | Phase 2 | Hepatocellular Carcinoma (HCC) |
Latest
No recent events.
Follow Brivanib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.